Details

Autor(en) / Beteiligte

• Riley, Christopher M.
• Elwood, Jessica M. L.
• Henry, Martyn C.
• Hunter, Irene
• Daniel Lopez‐Fernandez, J.
• McEwan, Iain J.
• Jamieson, Craig

Titel

Current and emerging approaches to noncompetitive AR inhibition

Ist Teil von

• Medicinal research reviews, 2023-09, Vol.43 (5), p.1701-1747

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2023

Quelle

Wiley Online Library All Journals

Beschreibungen/Notizen

• The androgen receptor (AR) has been shown to be a key determinant in the pathogenesis of castration‐resistant prostate cancer (CRPC). The current standard of care therapies targets the ligand‐binding domain of the receptor and can afford improvements to life expectancy often only in the order of months before resistance occurs. Emerging preclinical and clinical compounds that inhibit receptor activity via differentiated mechanisms of action which are orthogonal to current antiandrogens show promise for overcoming treatment resistance. In this review, we present an authoritative summary of molecules that noncompetitively target the AR. Emerging small molecule strategies for targeting alternative domains of the AR represent a promising area of research that shows significant potential for future therapies. The overall quality of lead candidates in the area of noncompetitive AR inhibition is discussed, and it identifies the key chemotypes and associated properties which are likely to be, or are currently, positioned to be first in human applications.